Lava Therapeutics Nv Stock Buy Hold or Sell Recommendation
| LVTX Stock | USD 1.29 0.06 4.44% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding LAVA Therapeutics NV is 'Strong Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell LAVA Therapeutics NV given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for LAVA Therapeutics NV, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out LAVA Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as LAVA and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards LAVA Therapeutics NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
LAVA |
Execute LAVA Therapeutics Buy or Sell Advice
The LAVA recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on LAVA Therapeutics NV. Macroaxis does not own or have any residual interests in LAVA Therapeutics NV or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute LAVA Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
2 Years |
Risk Tolerance
I am willing to take any risk |
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
LAVA Therapeutics Trading Alerts and Improvement Suggestions
| LAVA Therapeutics generated a negative expected return over the last 90 days | |
| LAVA Therapeutics has high historical volatility and very poor performance | |
| LAVA Therapeutics may become a speculative penny stock | |
| LAVA Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.77 M. Net Loss for the year was (41.7 M) with profit before overhead, payroll, taxes, and interest of 7.19 M. | |
| LAVA Therapeutics NV currently holds about 110.71 M in cash with (38.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 40.0% of the company outstanding shares are owned by corporate insiders |
LAVA Therapeutics Returns Distribution Density
The distribution of LAVA Therapeutics' historical returns is an attempt to chart the uncertainty of LAVA Therapeutics' future price movements. The chart of the probability distribution of LAVA Therapeutics daily returns describes the distribution of returns around its average expected value. We use LAVA Therapeutics NV price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of LAVA Therapeutics returns is essential to provide solid investment advice for LAVA Therapeutics.
| Mean Return | -0.28 |
| Value At Risk | -7.5 |
| Potential Upside | 5.36 |
| Standard Deviation | 7.44 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of LAVA Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
LAVA Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to LAVA Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that LAVA Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a LAVA stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.29 | |
β | Beta against Dow Jones | 0.13 | |
σ | Overall volatility | 7.44 | |
Ir | Information ratio | -0.04 |
LAVA Therapeutics Volatility Alert
LAVA Therapeutics NV is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure LAVA Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact LAVA Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.LAVA Therapeutics Fundamentals Vs Peers
Comparing LAVA Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze LAVA Therapeutics' direct or indirect competition across all of the common fundamentals between LAVA Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as LAVA Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of LAVA Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing LAVA Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare LAVA Therapeutics to competition |
| Fundamentals | LAVA Therapeutics | Peer Average |
| Return On Equity | -0.63 | -0.31 |
| Return On Asset | -0.18 | -0.14 |
| Operating Margin | (3.82) % | (5.51) % |
| Current Valuation | (37.09 M) | 16.62 B |
| Shares Outstanding | 26.3 M | 571.82 M |
| Shares Owned By Insiders | 40.40 % | 10.09 % |
| Shares Owned By Institutions | 31.11 % | 39.21 % |
| Number Of Shares Shorted | 25.12 K | 4.71 M |
| Price To Earning | 0.54 X | 28.72 X |
| Price To Book | 1.08 X | 9.51 X |
| Price To Sales | 4.62 X | 11.42 X |
| Revenue | 6.77 M | 9.43 B |
| Gross Profit | 7.19 M | 27.38 B |
| EBITDA | (40.42 M) | 3.9 B |
| Net Income | (41.7 M) | 570.98 M |
| Cash And Equivalents | 110.71 M | 2.7 B |
| Cash Per Share | 4.29 X | 5.01 X |
| Total Debt | 6.31 M | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 6.74 X | 2.16 X |
| Book Value Per Share | 1.25 X | 1.93 K |
| Cash Flow From Operations | (38.97 M) | 971.22 M |
| Short Ratio | 0.79 X | 4.00 X |
| Earnings Per Share | (1.01) X | 3.12 X |
| Target Price | 2.15 | |
| Number Of Employees | 37 | 18.84 K |
| Beta | 0.56 | -0.15 |
| Market Capitalization | 33.93 M | 19.03 B |
| Total Asset | 101.71 M | 29.47 B |
| Retained Earnings | (148.07 M) | 9.33 B |
| Working Capital | 83.96 M | 1.48 B |
| Net Asset | 101.71 M |
Note: Acquisition by Hurly Stephen A of 335100 shares of LAVA Therapeutics at 0.93 subject to Rule 16b-3 [view details]
LAVA Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as LAVA . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About LAVA Therapeutics Buy or Sell Advice
When is the right time to buy or sell LAVA Therapeutics NV? Buying financial instruments such as LAVA Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having LAVA Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for LAVA Stock Analysis
When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.